Clinical trials of a new drug class for preventing high-frequency episodic migraine and chronic migraine have shown promising results, according to several studies presented at the American Headache Society’s annual Scientific Meeting.
The new class of drugs, called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, is the first new class of medications to treat migraine since the development and marketing of triptans in 1991. However, unlike other drug classes, these medications are intended for preventative treatment in reducing elevated levels of CGRP that have been linked to migraine.
At the American Headache Society meeting, Teva reported for the first time that its experimental drug significantly reduced the number of headache hours after one week in a Phase 2b trial and more than half of patients in each arm had a ≥50% reduction in headache frequency. Eli Lilly also presented for the first time Phase 2 data that established the efficacy of their drug compared to placebo with monthly administration in a range of doses. Phase 2 results from Amgen indicate that its anti-CGRP drug reduced the number of migraine days by 50% in about half of patients after 12 weeks. Lastly, Alder Pharmaceutical shared details on their anti-CGRP drug with the publishing of positive Phase 2 data.
For more information visit AmericanHeadacheSociety.org.